Canton Hathaway’s Procept Biorobotics PRCT Stock Holding History

Canton Hathaway’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-820	Closed	-$66K	–	267
2024 Q3	$66K	Buy	+820	New	+$58.3K	0.02%	144

Other funds holding PRCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Canton Hathaway's PRCT Position: Q4 2024 in Review

Canton Hathaway sold out of Procept Biorobotics (PRCT) in Q4 2024, closing a stake of 820 shares — an estimated $66K sold.

Canton Hathaway first reported a position in PRCT in Q3 2024 and held it in 1 quarter. The position peaked at $66K in Q3 2024. 281 funds tracked by Wall St. Rank hold PRCT as of Q4 2024.

Canton Hathaway reported no remaining Procept Biorobotics position as of Q4 2024 after selling out during the quarter.
Canton Hathaway sold 820 Procept Biorobotics shares in Q4 2024, an estimated $66K.
Canton Hathaway first reported a position in Procept Biorobotics in Q3 2024 and held it in 1 quarter.
Canton Hathaway's Procept Biorobotics position peaked at $66K in Q3 2024.
281 funds tracked by Wall St. Rank held Procept Biorobotics as of Q4 2024.

Based on Canton Hathaway's 13F filing for Q4 2024, filed 4 Feb 2025.